The relationship between dysglycemia and cognitive dysfunction

Current Opinion in Investigational Drugs

Volumn 10, Issue 1, 2009, Pages 70-74

  Cukierman Yaffee, T ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cognitive dysfunction; Dementia; Diabetes; Insulin; Insulin resistance

Indexed keywords

INSULIN;

ALZHEIMER DISEASE; BRAIN LEVEL; COGNITIVE DEFECT; DEMENTIA; HUMAN; INSULIN RESISTANCE; MULTIINFARCT DEMENTIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PREVALENCE; REVIEW;

ANIMALS; BLOOD GLUCOSE; BRAIN; COGNITION DISORDERS; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; PREVALENCE;

EID: 58449097303     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27(5):1047-1053.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol (2003) 60(8):1119-1122.
3. Cukierman T, Hertzel HC, Williamson JD: Cognitive decline and dementia in diabetes - systematic review of prospective observational studies. Diabetologia (2005) 48(12):2460-2469. •• A systematic review and meta-analysis that summarized all prospective studies that followed people without dementia at baseline and compared the rate of cognitive decline and the incidence of dementia in people with and without diabetes, and provides quantitative estimates of the effect.
4. MacKnight C, Rockwood K, Awalt E, McDowell I: Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord (2002) 14(2):77-83.
5. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A: Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 54(11 Suppl 5):S4-S9.
6. Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH: Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol (2003) 60(10):1385-1389.
7. Allen KV, Frier BM, Strachan MW: The relationship between type 2 diabetes and cognitive dysfunction: Longitudinal studies and their methodological limitations. Eur J Pharmacol (2004) 490(1-3):169-175. •• An in depth summary of the literature supporting the diabetes cognitive dysfunction relationship.
8. Strachan MW, Deary IJ, Ewing FM, Frier BM: Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care (1997) 20(3):438-445.
9. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol (2004) 61(5):661-666.
10. Awad N, Gagnon M, Messier C: The relationship between impaired glucose tolerance, type 2 diabetes, and cognitive function. J Clin Exp Neuropsychol (2004) 26(8):1044-1080. •• A critical summary of published work demonstrating a relationship between diabetes and cognitive dysfunction. The review summarizes which cognitive domains seem to be affected and their relative effect size.
11. Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, Cummings SR: Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med (2000) 160(2):174-180.
12. Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ: Prevalence of dementia in older latinos: The influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc (2003) 51(2):169-177.
13. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L: The role of APOE ?4 in modulating effects of other risk factors for cognitive decline in elderly persons. J Am Med Assoc (1999) 282(1):40-46.
14. Hassing LB, Hofer SM, Nilsson SE, Berg S, Pedersen NL, McClearn G, Johansson B: Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: Evidence from a longitudinal study. Age Ageing (2004) 33(4):355-361.
15. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K: Change in cognitive function by glucose tolerance status in older adults: A 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med (2004) 164(12):1327-1333. • A prospective study comparing the rate of cognitive decline in pre-diabetes, diabetes and normoglycemia.
16. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR, Atherosclerosis Risk in Communities (ARIC) Study Investigators: Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology (2001) 56(1):42-48.
17. Logroscino G, Kang JH, Grodstein F: Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. Br Med J (2004) 328(7439):548.
18. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R: Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol (2001) 154(7):635-641.
19. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM: Association of diabetes mellitus and dementia: The Rotterdam Study. Diabetologia (1996) 39(11):1392-1397.
20. Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Ageing Study: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes (2002) 51(4):1256-1262.
21. Stewart R, Liolitsa D: Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med (1999) 16(2):93-112.
22. Yamada M, Kasagi F, Sasaki H, Masunari N, Mimori Y, Suzuki G: Association between dementia and midlife risk factors: The Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc (2003) 51(3):410-414. •• The Adult Health Study followed a cohort of atomic bomb survivors from Hiroshima and Nagasaki. They compared, after 34 to 39 years of follow up, the rate of Alzheimer's dementia and vascular dementia amongst people with diabetes and without diabetes at baseline.
23. Schnaider Beeri M, Goldbourt U, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, Sverdlick A, Davidson M: Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology (2004) 63(10):1902-1907.
24. Reichard P, Pihl M: Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes (1994) 43(2):313-317.
25. Musen G, Jacobson AM, Ryan CM, Cleary PA, Waberski BH, Weinger K, Dahms W, Bayless M, Silvers N, Harth J, White N: The impact of diabetes and its treatment on cognitive function among adolescents who participated in the Diabetes Control and Complications Trial. Diabetes Care (2008) 31(10):1933-1938. •• A follow-up study of the DCCT demonstrating the long term effect of intensive glucose control on hypoglycemia rate and on cognition in people with type 1 diabetes.
26. Shorr RI, de Rekeneire N, Resnick HE, Yaffe K, Somes GW, Kanaya AM, Simonsick EM, Newman AB, Harris TB: Glycemia and cognitive function in older adults using glucose-lowering drugs. J Nutr Health Aging (2006) 10(4):297-301.
27. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Launer LJ, for the MIND substudy investigators: The Relationship Between Baseline Glycemia & Cognitive Function in People with Type 2 Diabetes & Other Cardiovascular Risk Factors: The ACCORD-MIND Study. Diabetes (2008) 57(Suppl 1):A75.
28. Cukierman-Yaffe T, Gerstein HC, Anderson C, Zhao F, Sleight P, Hilbrich L, Yusuf S, Teo K, on behalf of the ONTARGET/TRANSCEND Investigators: Diabetes status and fasting plasma glucose are independent determinants of cognitive status in people at high risk for cardiovascular disease. Diabetologia (2006) 49(Suppl 1): Abs 0118.
29. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K: Diabetes impaired fasting glucose and development of cognitive impairment in older women. Neurology (2004) 63(4):658-663.
30. Horie K, Miyata T, Yasuda T, Takeda A, Yasuda Y, Maeda K, Sobue G, Kurokawa K: Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Biochem Biophys Res Commun (1997) 236(2):327-332.
31. Vlassara H, Bucala R, Striker L: Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest (1994) 70(2):138-151.
32. Sabayan B, Foroughinia F, Mowla A, Borhanihaghighi A: Role of insulin metabolism disturbances in the development of Alzheimer disease: Mini review. Am J Alzheimers Dis Other Demen (2008) 23(2):192-199.
33. Plum L, Belgardt BF, Bruning JC: Central insulin action in energy and glucose homeostasis. J Clin Invest (2006) 116(7):1761-1766.
34. Salkovic-Petrisic M, Hoyer S: Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: An experimental approach. J Neural Transm Suppl (2007) (72):217-233.
35. Voll CL, Auer RN: Insulin attenuates ischemic brain damage independent of its hypoglycemic effect. J Cereb Blood Flow Metab (1991) 11(6):1006-1014.
36. Watson GS, Craft S: Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer's disease. Eur J Pharmacol (2004) 490(1-3):97-113.
37. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006) 6(4):246-254. •• A randomized controlled trial of people with dementia and pre-dementia that were treated with an insulin sensitizer.
38. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, Craft S: Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-β in memory-impaired older adults. J Alzheimers Dis (2008) 13(3):323-331. •• The use of intranasal insulin in people with Alzheimer's disease.
39. Young SE, Mainous AG 3rd, Carnemolla M: Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care (2006) 29(12):2688-2693. •• A prospective study demonstrating the relationship between high insulin levels in mid-life and the rate of cognitive decline.
40. Okereke OI, Pollak MN, Hu FB, Hankinson SE, Selkoe DJ, Grodstein F: Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoneuroendocrinology (2008) 33(4):455-461.
41. Okereke OI, Kang JH, Ma J, Gaziano JM, Grodstein F: Midlife plasma insulin-like growth factor I and cognitive function in older men. J Clin Endocrinol Metab (2006) 91(11):4306-4312.